Trial Profile
A Multicenter, Open-Label, Phase 3 Clinical Study to Evaluate the Immunogenicity and Safety of IL-YANG Inactivated Split Influenza Vaccine in Healthy Adults 18 to ' 65 Years of Age and in Healthy Adults ≥ 65 Years of Age.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Jun 2014
Price :
$35
*
At a glance
- Drugs IL Yang Flu Vaccine (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors Il-Yang
- 13 Jun 2014 New trial record